Company profile

Nuvation Bio Inc.

Pipeline4 assets

TaletrectinibIBTROZI / ROS1 / Small Molecule / Oncology
Advanced ROS1+ NSCLC
SafusidenibmIDH1 / Small Molecule / Oncology
Diffuse IDH1-mutant gliomaAstrocytomaOligodendroglioma
NUV-1511NUV-1511 / Undisclosed / Drug-Drug Conjugate (DDC) / Oncology
Advanced solid tumors
NUV-868NUV-868 / BET (BD2-selective) / Small Molecule / Oncology
Advanced solid tumors

Latest news16 items

May 27, 2026

Nuvation Bio to Present at the Jefferies Global Healthcare Conference

May 27, 2026

Nuvation Bio to Present New Quality-of-Life Data for IBTROZI® (Taletrectinib) in Patients with ROS1-Positive Non-Small Cell Lung Cancer at ASCO 2026 Annual Meeting

May 13, 2026

Nuvation Bio to Collaborate with Thermo Fisher Scientific for U.S.-Based Manufacturing of IBTROZI® for ROS1-Positive Non-Small Cell Lung Cancer

May 6, 2026

Nuvation Bio Announces FDA Acceptance of Supplemental New Drug Application for IBTROZI® (taletrectinib) with Updated Duration of Response in Advanced ROS1-Positive Non-Small Cell Lung Cancer

May 5, 2026

Nuvation Bio to Participate in Upcoming Investor Conferences

May 4, 2026

Nuvation Bio Reports First Quarter 2026 Financial Results and Provides Business Update

Apr 27, 2026

Nuvation Bio Announces National Comprehensive Cancer Network® Adds Taletrectinib (IBTROZI®) as Recommended Option to Clinical Practice Guidelines in Oncology for Central Nervous System Cancers

Apr 21, 2026

Nuvation Bio Announces IBTROZI® (Taletrectinib) Showed Highly Durable Responses in Longer-Term Follow-up Data from Pivotal Studies Presented at AACR 2026

Presentation / Abstract

Apr 20, 2026

Nuvation Bio to Report First Quarter 2026 Financial Results and Provide Business Update on May 4, 2026

Apr 1, 2026

Nuvation Bio Announces Acquisition of Japan Rights to Safusidenib from Daiichi Sankyo

Mar 26, 2026

Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency

Mar 17, 2026

Nuvation Bio to Present Pivotal IBTROZI® (Taletrectinib) Data in TKI-Naïve and TKI-Pretreated Patients with Advanced ROS1-Positive Non-Small Cell Lung Cancer at AACR 2026

Mar 2, 2026

Nuvation Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Feb 25, 2026

Nuvation Bio to Participate in Upcoming Investor Conferences

Feb 17, 2026

Nuvation Bio to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 2, 2026

Feb 9, 2026

Nuvation Bio Announces Pivotal Global Phase 3 SIGMA Trial (G203) for Safusidenib in IDH1-Mutant Glioma

Nuvation Bio Inc. • Endpoint Arena